CML clonal evolution with resistance to single agent imatinib therapy

被引：7

作者：

Swords, R ^{[1
]}

Quinn, J ^{[1
]}

Fay, M ^{[1
]}

O'Donnell, R ^{[1
]}

Goldman, J ^{[1
]}

Murphy, PT ^{[1
]}

机构：

[1] Beaumont Hosp, Dept Haematol, Dublin 9, Ireland

来源：

CLINICAL AND LABORATORY HAEMATOLOGY | 2005年 / 27卷 / 05期

关键词：

chronic myeloid leukaemia; imatinib; clonal evolution; resistance; Philadelphia chromosome;

D O I：

10.1111/j.1365-2257.2005.00721.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We describe a 58-year-old male diagnosed with chronic myeloid leukaemia (CML) who failed to have a cytogenetic response to interferon-alpha and hydroxyurea. On subsequent therapy with imatinib mesylate he failed to have any cytogenetic response but also developed a complex clonal evolution with an additional Philadelphia (Ph) chromosome and trisomy 8 respectively in two Ph-positive subclones. The addition of cytosine arabinoside to imatinib resulted in reversion to single Ph-chromosome positivity with the disappearance of the previous additional clonal abnormalities. The case demonstrates the efficacy of combined treatment with imatinib and cytarabine in the management of CML resistant to single agent imatinib.

引用

页码：347 / 349

页数：3

共 12 条

[1] Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Branford, S
Rudzki, Z
Walsh, S
Parkinson, I
Grigg, A
Szer, J
Taylor, K
Herrmann, R
Seymour, JF
Arthur, C
Joske, D
Lynch, K
Hughes, T
[J]. BLOOD, 2003, 102 (01) : 276 - 283
[2] Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
Cortes, JE
Talpaz, M
Giles, F
O'Brien, S
Rios, MB
Shan, J
Garcia-Manero, G
Faclerl, S
Thomas, DA
Wierda, W
Ferrajoli, A
Jeha, S
Kantarjian, HM
[J]. BLOOD, 2003, 101 (10) : 3794 - 3800
[3] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
Golemovic, M
Verstovsek, S
Giles, F
Cortes, J
Manshouri, T
Manley, PW
Mestan, J
Dugan, M
Alland, L
Griffin, JD
Arlinghaus, RB
Sun, T
Kantarjian, H
Beran, M
[J]. CLINICAL CANCER RESEARCH, 2005, 11 (13) : 4941 - 4947
[4] InBCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C
Kindler, T
Breitenbuecher, F
Kasper, S
Stevens, T
Carius, B
Gschaidmeier, H
Huber, C
Fischer, T
[J]. LEUKEMIA, 2003, 17 (06) : 999 - 1009
[5] In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines
La Rosée, P
Johnson, K
Corbin, AS
Stoffregen, EP
Moseson, EM
Willis, S
Mauro, MM
Melo, JV
Deininger, MW
Druker, BJ
[J]. BLOOD, 2004, 103 (01) : 208 - 215
[6] Marktel S, 2003, HAEMATOLOGICA, V88, P260
[7] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
O'Brien, SG
Guilhot, F
Larson, RA
Gathmann, I
Baccarani, M
Cervantes, F
Cornelissen, JJ
Fischer, T
Hochhaus, A
Hughes, T
Lechner, K
Nielsen, JL
Rousselot, P
Reiffers, J
Saglio, G
Shepherd, J
Simonsson, B
Gratwohl, A
Goldman, JM
Kantarjian, H
Taylor, K
Verhoef, G
Bolton, AE
Capdeville, R
Druker, BJ
Durrant, S
Schwarer, A
Joske, D
Seymour, J
Grigg, A
Ma, D
Arthur, C
Bradstock, K
Joshua, D
Louwagie, A
Martiat, P
Straetmans, N
Bosly, A
Shustik, C
Lipton, J
Forrest, D
Walker, I
Roy, DC
Rubinger, M
Bence-Bruckler, I
Kovacs, M
Turner, AR
Birgens, H
Bjerrum, O
Facon, T
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) : 994 - 1004
[8] Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
O'Hare, T
Pollock, R
Stoffregen, EP
Keats, JA
Abdullah, OM
Moseson, EM
Rivera, VM
Tang, H
Metcalf, CA
Bohacek, RS
Wang, YH
Sundaramoorthi, R
Shakespeare, WC
Dalgarno, D
Clackson, T
Sawyer, TK
Deininger, MW
Druker, BJ
[J]. BLOOD, 2004, 104 (08) : 2532 - 2539
[9] Resistance to imatinib: more and more mutations
Sawyers, CL
[J]. BLOOD, 2003, 102 (01) : 4 - 5
[10] Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Shah, NP
Nicoll, JM
Nagar, B
Gorre, ME
Paquette, RL
Kuriyan, J
Sawyers, CL
[J]. CANCER CELL, 2002, 2 (02) : 117 - 125

← 1 2 →